OncoArendi continues to grow by executing further steps of the strategy and initiates two new drug discovery programs within its existing research platforms

According to the strategy released in March, OncoArendi Therapeutics S.A. (WSE: OAT) expands its existing innovative drug discovery platforms by launching two new programs: CHIT1 SELECTIVE focusing on new therapeutic areas within the chitinase platform and a new program in the deubiquitinase (DUBs) platform in oncology indications. These activities are in line with strategic plans announced for the coming years leading to dynamic growth and expansion into new therapeutic targets.

Magda KućmaOncoArendi continues to grow by executing further steps of the strategy and initiates two new drug discovery programs within its existing research platforms
Czytaj więcej

Galapagos informed about the initiation of a clinical trial to evaluate potential pharmacokinetic interactions of GLPG4716

Galapagos has posted on CT.gov (https://clinicaltrials.gov/ct2/show/NCT04971746) the start of a clinical trial with GLPG4716 (OATD-01) to evaluate potential pharmacokinetic drug-drug interactions with pirfenidone and nintedanib, which are drugs that are approved and standard of care for treatment of idiopathic pulmonary fibrosis (IPF). Since in a future phase 2 trial in IPF patients GLPG4716 (OATD-01) would have to be given on top of standard of care, it is important to investigate at what doses GLPG4716 can be combined with these drugs.

Magda KućmaGalapagos informed about the initiation of a clinical trial to evaluate potential pharmacokinetic interactions of GLPG4716
Czytaj więcej

OncoArendi executes the strategy for 2021-2025 in the area of R&D platform for developing small molecules modulating RNA function

· On June 16 2021, the Company signed a scientific cooperation agreement with the International Institute of Molecular and Cell Biology in Warsaw (IIMCB) in the field of discovery and development of small molecule drugs modulating the function of RNA

· OncoArendi also entered exclusive negotiations with IIMCB of a licensing agreement (License Execution Agreement) for the rights to a unique bioinformatics software (the Bioinformatics Platform)

The agreement signed between OncoArendi and IIMCB launches a new, strategic area of research cooperation. It focuses on the development of the SMR Platform, i.e. the platform of small molecules targeting RNA. Discovery and development of small molecule drugs modulating RNA function with the use of innovative bioinformatic tools is one of the three key R&D areas of the Company’s strategy for growth in 2021-2025.

Magda KućmaOncoArendi executes the strategy for 2021-2025 in the area of R&D platform for developing small molecules modulating RNA function
Czytaj więcej

OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhibitors in fibrosis

Mechelen, Belgium and Warsaw, Poland, 5 November 2020, 22:15 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and OncoArendi Therapeutics SA (WSE: OAT), announced that they have signed an exclusive collaboration and license agreement for the global development and commercialization of OncoArendi’s OATD-01. OATD-01 is a Phase 2-ready chitotriosidase/acidic mammalian chitinase (CHIT1/AMCase) inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and other diseases with a fibrotic component.   

Lung diseases like IPF are associated with an increased chitinase activity, which strongly correlates with disease stage, progression and prognosis. Chitinases (predominantly CHIT1) are involved in macrophage activation. Inhibition of chitinase activity translates into a potential therapeutic benefit, as shown in a range of preclinical models. OATD-01 has shown robust anti-fibrotic activity in multiple animal models, when compared with the standard of care.

meatnetadmOncoArendi and Galapagos enter into exclusive collaboration on chitinase inhibitors in fibrosis
Czytaj więcej

American Journal of Medicinal Chemistry distinguishes OncoArendi publication on OATD-01

A new publication about the discovery and preclinical characterization of OATD-01, authored by the scientists from OncoArendi Therapeutics, has just been accepted by the Journal of Medicinal Chemistry (J. Med. Chem). OATD-01 is a first-in-class chitinase inhibitor, which had recently completed Phase I studies and continues its development as a clinical candidate for the treatment of sarcoidosis, idiopathic pulmonary fibrosis (IPF), and possibly other fibrotic and inflammatory diseases.

Magda KućmaAmerican Journal of Medicinal Chemistry distinguishes OncoArendi publication on OATD-01
Czytaj więcej

OncoArendi Therapeutics expands the therapeutic potential of its Chitinase Platform

OncoArendi develops OATD-01 as a drug candidate for treatment of severe inflammatory and fibrotic diseases. Clinical trials in patients must be preceded by a number of preclinical safety studies, including GLP standard chronic toxicology. Such studies, outsourced to Charles River (USA), a leading global CRO (Contract Research Organization) have recently completed dosing. The 6 and 9 month period of administration of OATD-01 in rats and dogs (respectively) has just ended. A recovery phase of several weeks is currently ongoing. Preliminary reports of these studies are expected at the end of January 2021, while the final reports will be obtained in the second half of 2021. It should be emphasized that previously completed 17-week toxicology studies, also performed by Charles River, already enable Phase IIa studies in sarcoidosis patients to begin early next year.

Magda KućmaOncoArendi Therapeutics expands the therapeutic potential of its Chitinase Platform
Czytaj więcej

OncoArendi Therapeutics broadens its collaboration with VIB, a leading life science research institute in Europe, to investigate the role of chitinase family of proteins as potential therapeutic targets in COVID-19 patients

OncoArendi Therapeutics SA today signed an agreement with VIB, one of the world leading life science research institutes. The scope of this research collaboration focuses on the role of chitinase and chitinase-like-proteins (CLPs) in COVID-19 and subsequent complication. This collaboration can lead to identification of new drug candidates that can alleviate COVID-19 complications, such as lung fibrosis.

Magda KućmaOncoArendi Therapeutics broadens its collaboration with VIB, a leading life science research institute in Europe, to investigate the role of chitinase family of proteins as potential therapeutic targets in COVID-19 patients
Czytaj więcej

OncoArendi Therapeutics has received the final report from the phase Ib clinical trial of innovative drug candidate OATD-01

  •  the report confirms the OATD-01 safety profile which justifies further clinical development of this experimental drug
  • In Q1 of 2021 the company plans to file for an approval of the next phase clinical trial in sarcoidosis patients

OncoArendi Therapeutics S.A. (GPW: OAT) — a biotechnology company which specializes in discovery and development of new drugs will continue the clinical development of the OATD-01 molecule — an innovative small molecule chitinase inhibitor — in the treatment of severe pulmonary diseases such as sarcoidosis or idiopathic pulmonary fibrosis (IPF). OncoArendi Therapeutics is the first and so far only biotechnology company in the world, which conducts clinical trials of drug candidates targeting chitinase (first-in-class).

Magda KućmaOncoArendi Therapeutics has received the final report from the phase Ib clinical trial of innovative drug candidate OATD-01
Czytaj więcej

Dr. Zbigniew Zasłona joins OncoArendi Therapeutics as the new Director of the Biology Department. Dr Paweł Dobrzański, the current head of the Biology Department, will still be engaged in collaboration with OncoArendi as Senior Scientific Advisor on the company’s Scientific Advisory Board.

Dr. Zbigniew Zasłona, a biologist and scientist with impressive achievements in the area of pulmonary diseases (at Trinity College Dublin since 2015) has joined the research team of OncoArendi Therapeutics S.A. Prior to his collaboration with OncoArendi dr. Zasłona was a Senior Investigator at a biopharmaceutical company Sitryx, where he was responsible for studies on new therapeutic targets in the field of immunometabolism (development of anti-inflammatory medicines).

Magda KućmaDr. Zbigniew Zasłona joins OncoArendi Therapeutics as the new Director of the Biology Department. Dr Paweł Dobrzański, the current head of the Biology Department, will still be engaged in collaboration with OncoArendi as Senior Scientific Advisor on the company’s Scientific Advisory Board.
Czytaj więcej

Dr Timi Oshodi joined OncoArendi Therapeutics

OncoArendi Therapeutics – a biotechnology company specializing in the discovery, development and commercialization of innovative drugs, has hired Dr. Timi Oshodi as Director of Preclinical Development. Dr. Oshodi will be responsible for planning and implementing of preclinical safety and pharmacokinetic studies for molecules developed by the company.

Magda KućmaDr Timi Oshodi joined OncoArendi Therapeutics
Czytaj więcej